Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step [TheStreet.com]
Is It Too Late To Consider Madrigal Pharmaceuticals (MDGL) After Recent Share Price Surge? [Yahoo! Finance]
Advanced Cell-based Therapy Booming the Success for Healthcare Sector [Globe and Mail, The (Toronto, Canada)]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)